A delicate dance: Balancing cancer care and pregnancy.
The American Society of Clinical Oncology (ASCO) has released a crucial guideline, shedding light on the intricate balance required when treating cancer in pregnant patients. This guideline, published in the Journal of Clinical Oncology, addresses the unique challenges faced by both the expectant mother and her unborn child.
A Rare Yet Impactful Intersection
Dr. Mikkael A. Sekeres, Chief of Hematology at Sylvester Comprehensive Cancer Center, highlights the rarity of cancer diagnoses during pregnancy, occurring in only about 1 in 1000 to 2000 pregnancies. However, he emphasizes the profound medical and psychosocial implications that arise when these two critical health concerns intersect.
"It's a delicate dance," Dr. Sekeres told Oncology News Central (ONC). "We must consider the aggressiveness of the cancer, the potential toxicity of treatments, and the patient's goals, all while ensuring the health of the fetus."
Evidence-Based, Yet Limited
The guideline, an evidence-based resource, tackles key clinical questions regarding diagnostic criteria, cancer management, and obstetrical considerations. However, the evidence used to craft these recommendations is primarily based on retrospective studies, case series, and individual reports, which, while valuable, present limitations due to potential biases and small sample sizes.
"The recommendations are strong, providing real-world data to guide practice," the guideline authors write. "But we must acknowledge the limitations of the evidence base."
Prioritizing Patient Preferences and Autonomy
Dr. Ann H. Partridge, Director of the Adult Survivorship Program at Dana-Farber Cancer Institute, underscores the importance of patient preferences and autonomy in decision-making. She highlights the need to consider the patient's desire to maintain the pregnancy, the risks of the disease and treatment options, and the potential risks to the fetus.
"It's a complex decision-making process," Dr. Partridge told ONC. "We must be transparent about what we know and don't know, both from a data perspective and for the individual patient."
A Multidisciplinary Approach
Key recommendations include the involvement of a multidisciplinary team, including pharmacists, to develop and adjust individualized treatment plans. Clinicians are encouraged to engage patients and caregivers in informed consent discussions before starting any form of therapy.
"Patient autonomy is paramount," the guideline states. "However, in medical emergencies, the risk of death to the pregnant patient may necessitate the termination of the pregnancy."
The Challenge of Teratogenic Drugs
One of the most challenging aspects is the use of drugs with unknown teratogenic potential. Dr. Sekeres notes that the evidence base for these recommendations is limited, primarily consisting of retrospective studies and case reports.
"Newer therapies, such as bispecific agents and antibody-drug conjugates, are often excluded from trials leading to drug registration," Dr. Partridge explained. "We're left with limited data and difficult decisions."
When asked about the teratogenic risks of these newer therapies, Dr. Partridge replied, "These risks are not well understood, and studying them is challenging due to the rarity of the patient population."
Expert Disclosures
Dr. Sekeres disclosed consulting and advisory roles with several pharmaceutical companies and institutional research funding. Dr. Partridge reported royalties from Wolters Kluwer for authorship with UpToDate.
This guideline provides a comprehensive framework for managing cancer care during pregnancy, but it also highlights the need for further research and a nuanced approach to decision-making.
What are your thoughts on this delicate balance? Share your insights and experiences in the comments below!
